The facility – which will take on 30 employees – will work with new data analysis methods, software, and systems to better predict the safety and efficacy of developmental drug candidates.
Plans there include developing mathematical models of bacterial cells, as well as those that the interaction of infectious agents with the human body and the immune system.
The company may also use the center to develop mathematical models of bacterial cells, as well as those that the interaction of infectious agents with the human body and the immune system.
AstraZeneca scientific project manager Elmira Safarova, who is based in Russia, said the firm hopes the new facility will bring its R&D expertise in the field of bioinformatics to the forefront in the Russian market.
Safarova added: “The new center in St. Petersburg will be one of the two R&D bioinformatics centers established by the company globally—another center is already located in Shanghai.
“We hope that this new R&D center will help to bring new discoveries, which will contribute to better health and quality of life of Russian patients.”